Skip to content

Quality of Life in Women With X-linked Adrenoleukodystrophy

Quality of Life in Female Carriers of X-linked Adrenoleukodystrophy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04675749
Acronym
X-ALD_QoL
Enrollment
200
Registered
2020-12-19
Start date
2019-12-01
Completion date
2028-03-01
Last updated
2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X-linked Adrenoleukodystrophy

Keywords

Adrenoleukodystrophy, Adrenomyeloneuropathy, Brain Diseases, Metabolic, Inborn, Central Nervous System Diseases, Demyelinating Diseases, White Matter Disorder, Genetic Diseases, X-Linked, Peroxisomal Disorders, Metabolic Diseases, Female Carrier, Adrenoleukodystrophy, women, Heterozygous Carrier, Quality of Life

Brief summary

X-linked adrenoleukodystrophy (X-ALD) is a hereditary white matter disorder caused by mutations in the ABCD1 gene leading to disturbances in the metabolism of fatty acids. This results in an accumulation of very long chain fatty acids (VLCFA) in the cells of the body causing damage to the central nervous system (white matter of the brain and spinal cord). The most common adult-onset X-ALD phenotype is adrenomyeloneuropathy (AMN), a slowly progressive myelopathic variant with demyelination of the long tracts in the spinal cord, clinically manifested as slowly progressive spastic paraparesis, sensory ataxia, bladder and sexual dysfunction. Although this rare disease is inherited X-linked, previous research revealed that up to 80% of heterozygous women develop AMN symptoms during their lifetime. The primary objectives of this study are 1) to assess the prevalence of symptomatic courses in female carriers of X-ALD and 2) to determine the impact of AMN symptoms on the quality of life of affected women in various areas (including everyday life, work, social network, sleep quality, sexuality, mood). Participants are asked to fill in self-report questionnaires, which are available in English, German, French, Spanish, and Italian, and are provided electronically on the online platform Leuconnect (https://www.leuconnect.com) launched by European Leukodystrophies Association (ELA) international (https://elainternational.eu/).

Interventions

None listed

Sponsors

Leipzig University Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed consent obtained from the participant * Females ≥18 years at the time of consent, with proven X-ALD as defined by 1. Elevated VLCFA values, or 2. Mutation in ABCD1 gene

Exclusion criteria

* No informed consent and assent * Current pregnancy

Design outcomes

Primary

MeasureTime frame
Number of Participants with AMN Symptoms as Assessed by Adult ALD Clinical Score (AACS) - self-report versionDay 0
Quality of Life in Symptomatic versus Asymptomatic Participants as Assessed by Self-report Questionnaire (SF-36)Day 0

Countries

Germany

Contacts

CONTACTLisa Schäfer, PhD
lisa.schaefer@medizin.uni-leipzig.de+49-341-9720086
PRINCIPAL_INVESTIGATORWolfgang Köhler, MD

Leipzig University Medical Center, Leukodystrophy Outpatient Clinic, Department of Neurology, Leipzig, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026